 Connection
Thomas Morrison to Antibodies, Monoclonal
This is a "connection" page, showing publications Thomas Morrison has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.377 |
|
|
|
-
Powell LA, Fox JM, Kose N, Kim AS, Majedi M, Bombardi R, Carnahan RH, Slaughter JC, Morrison TE, Diamond MS, Crowe JE. Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease. PLoS Pathog. 2020 05; 16(5):e1008517.
Score: 0.111
-
Hong JP, McCarthy MK, Davenport BJ, Morrison TE, Diamond MS. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody. J Virol. 2019 12 15; 93(24).
Score: 0.107
-
Hawman DW, Fox JM, Ashbrook AW, May NA, Schroeder KMS, Torres RM, Crowe JE, Dermody TS, Diamond MS, Morrison TE. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence. Cell Rep. 2016 08 02; 16(5):1326-1338.
Score: 0.085
-
Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, Axthelm MK, Vanlandingham DL, Streblow DN, Higgs S, Morrison TE, Diamond MS. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol. 2014 Aug; 88(15):8213-26.
Score: 0.073
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|